The combination of Sovaldi (sofosbuvir) plus Rebetol (ribavirin) has already been approved by the Food and Drug Administration (FDA) in the United States. The cure rates were 82% to 97%. The combination is being evaluated to receive marketing approval in Japan.
Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
To read the entire clinical trial description, click here…Share This Page